Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin‐treated patients

Summary.  Objectives: Although the concept of aspirin resistance is extensively reported in medical literature, its precise mechanisms and clinical outcomes are largely unknown. In this study, we examined individual thromboxane biosynthesis and platelet aggregation in aspirin‐treated patients, and whether the results of a platelet aggregation test influenced clinical outcomes. Results: Subjects taking 81 mg of aspirin (n = 50) and controls (n = 38) were evaluated for platelet aggregation and platelet cyclooxygenase‐1 (COX‐1) activity by measuring collagen‐induced thromboxane B2 production. For aggregometry, both light transmission (LT) and laser‐light scattering methods were employed to quantitatively evaluate aggregate sizes and numbers. Aspirin treatment resulted in the inhibition of collagen‐induced platelet aggregation, particularly the transition from small to large platelet aggregates. Although platelet COX‐1 activity seemed to be uniformly inhibited in all patients, platelet aggregation studies showed great inter‐individual differences; variation in platelet COX‐1 activity only accounted for 6–20% of the individual aggregations. Factor analysis revealed the existence of a common factor (other than platelet COX‐1) that explained 48.4% of the variations in platelet aggregation induced by collagen, adenosine diphosphate (ADP), and collagen‐related peptide. We then prospectively enrolled 136 aspirin‐treated patients in our study, and we found that being in the upper quartile level of LT, or with large aggregate formation induced by collagen, was an independent risk factor for developing cardiovascular events within 12 months [hazard ratio (HR) = 7.98, P = 0.008 for LT; HR = 7.76, P = 0.007 for large aggregates]. On the other hand, the existence of diabetes mellitus was an independent risk factor for overall outcomes (HR 1.30–11.9, P = 0.015–0.033). Conclusions: Aspirin resistance expressed as unsuppressed platelet COX‐1 activity is a rare condition in an out‐patient population. Other factor(s) affecting collagen‐induced platelet aggregation may influence early outcomes in aspirin‐treated patients.

[1]  A. Jacobs,et al.  Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.

[2]  A. Skene,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. , 2005, The New England journal of medicine.

[3]  Timi Study,et al.  Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation , 2005 .

[4]  M. Cattaneo.  Aspirin and Clopidogrel: Efficacy, Safety, and the Issue of Drug Resistance , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Chris I. Jones,et al.  Platelet inhibition by aspirin is diminished in patients during carotid surgery: a form of transient aspirin resistance? , 2004, Thrombosis and Haemostasis.

[6]  Andrew S. Holmes,et al.  Effect of perindopril on platelet nitric oxide resistance in patients with chronic heart failure secondary to ischemic left ventricular dysfunction. , 2004, The American journal of cardiology.

[7]  S. Martinotti,et al.  A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. , 2004, JAMA.

[8]  Chris I. Jones,et al.  Beneficial Effects of Clopidogrel Combined With Aspirin in Reducing Cerebral Emboli in Patients Undergoing Carotid Endarterectomy , 2004, Circulation.

[9]  G. FitzGerald,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[10]  P. Fontana,et al.  Adenosine Diphosphate–Induced Platelet Aggregation Is Associated With P2Y12 Gene Sequence Variations in Healthy Subjects , 2003, Circulation.

[11]  K. Schrör,et al.  Functional and Biochemical Evaluation of Platelet Aspirin Resistance After Coronary Artery Bypass Surgery , 2003, Circulation.

[12]  E. Topol,et al.  A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.

[13]  M. Halushka,et al.  Genetic variation in cyclooxygenase 1: Effects on response to aspirin , 2003, Clinical pharmacology and therapeutics.

[14]  D. Sane,et al.  Aspirin Resistance in Cardiovascular Disease: A Review of Prevalence, Mechanisms, and Clinical Significance , 2002, Thrombosis and Haemostasis.

[15]  C. Patrono,et al.  Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  M. Halushka,et al.  Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? , 2002, Circulation.

[17]  S. Yusuf,et al.  Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.

[18]  C. Patrono,et al.  Oxidant Stress and Aspirin-Insensitive Thromboxane Biosynthesis in Severe Unstable Angina , 2000, Circulation.

[19]  K. Kugiyama,et al.  Rapid Change of Platelet Aggregability in Acute Hyperglycemia , 2000, Thrombosis and Haemostasis.

[20]  J. Kambayashi,et al.  Increased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. , 2000, Stroke.

[21]  J. Meyer-Kirchrath,et al.  Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance , 1999, The Lancet.

[22]  V. Fuster,et al.  Platelet-active drugs: the relationships among dose, effectiveness, and side effects. , 2004, Chest.

[23]  T. Wells,et al.  Platelet Activation and Signal Transduction by Convulxin, a C-type Lectin from Crotalus durissus terrificus (Tropical Rattlesnake) Venom via the p62/GPVI Collagen Receptor* , 1997, The Journal of Biological Chemistry.

[24]  Y. Ozaki,et al.  Phosphorylation of Myosin Light Chain in Resting Platelets From NIDDM Patients Is Enhanced: Correlation With Spontaneous Aggregation , 1997, Diabetes.

[25]  J. Horowitz,et al.  Impaired Responsiveness of Platelets from Patients with Stable Angina Pectoris to Antiaggregating and CyclicAMP‐Elevating Effects of Prostaglandin E1 , 1995, Journal of cardiovascular pharmacology.

[26]  R. Young,et al.  Integrin alpha 2 beta 1-independent activation of platelets by simple collagen-like peptides: collagen tertiary (triple-helical) and quaternary (polymeric) structures are sufficient alone for alpha 2 beta 1-independent platelet reactivity. , 1995, The Biochemical journal.

[27]  Y Ozaki,et al.  Detection of platelet aggregates with a particle counting method using light scattering. , 1994, Analytical biochemistry.

[28]  Walker,et al.  Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients , 1994 .

[29]  G. FitzGerald,et al.  11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Watanabe,et al.  High concentrations of arachidonic acid induce platelet aggregation and serotonin release independent of prostaglandin endoperoxides and thromboxane A2. , 1985, Biochimica et biophysica acta.

[31]  E. Granström,et al.  Radioimmunoassay of prostaglandins and thromboxanes. , 1978, Advances in prostaglandin and thromboxane research.

[32]  I. Peake.  International Society on Thrombosis and Haemostasis , 1974, Thrombosis and Haemostasis.

[33]  G. Born,et al.  Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.